Back to Journals » ImmunoTargets and Therapy » Volume 6

ESCI
SJR OA
CiteScore
Impact Factor

ImmunoTargets and Therapy

ISSN: 2253-1556


       

Archive: Volume 6, 2017

Review

The current status of immunobased therapies for metastatic renal-cell carcinoma

Sathianathen NJ, Krishna S, Anderson JK, Weight CJ, Gupta S, Konety BR, Griffith TS

ImmunoTargets and Therapy 2017, 6:83-93

Published Date: 5 December 2017

Review

Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review

Yoest JM

ImmunoTargets and Therapy 2017, 6:73-82

Published Date: 10 October 2017

Review

Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events

Davies M, Duffield EA

ImmunoTargets and Therapy 2017, 6:51-71

Published Date: 24 August 2017

Original Research

CD8+ memory T-cell inflation renders compromised CD4+ T-cell-dependent CD8+ T-cell immunity via naïve T-cell anergy

Xu A, Freywald A, Xie Y, Li Z, Xiang J

ImmunoTargets and Therapy 2017, 6:39-49

Published Date: 15 June 2017

Review

Targeting innate immunity to downmodulate adaptive immunity and reverse type 1 diabetes

Itoh A, Ridgway WM

ImmunoTargets and Therapy 2017, 6:31-38

Published Date: 19 May 2017

Review

FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights

Krakauer T

ImmunoTargets and Therapy 2017, 6:17-29

Published Date: 2 May 2017

Clinical Trial Report

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer

Scholz M, Yep S, Chancey M, Kelly C, Chau K, Turner J, Lam R, Drake CG

ImmunoTargets and Therapy 2017, 6:11-16

Published Date: 20 March 2017

Review

First-line treatment of metastatic melanoma: role of nivolumab

Force J, Salama AK

ImmunoTargets and Therapy 2017, 6:1-10

Published Date: 13 February 2017